Health ❯ Pharmaceuticals ❯ Biotechnology

Corporate Ethics

Misleading Statements Regulatory Compliance

ImmunityBio Investors Face May 26 Lead-Plaintiff Deadline in Securities Suit Tied to FDA Anktiva Rebuke

The case stems from an FDA warning that promotional claims for Anktiva were false or misleading, which drove a roughly 21% stock drop on March 24.

ImmunityBio Investors Face May 26 Deadline in Securities Class Action Over FDA Ad Rebuke